News Releases

Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the Kidney with Presentations at Upcoming Medical Meetings

October 18, 2018

NEWTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced presentations at two upcoming medical meetings. At the 2018 American College of Rheumatology (ACR/ARHP) Annual Meeting held October 19-24th in Chicago, IL, the company will present proof-of-concept data for ALLN-346, its lead product candidate for the treatment of hyperuricemia in the setting of advanced chronic kidney disease (CKD). In addition, at the American Society of Nephrology (ASN) Kidney Week 2018 held October 23-28th in San Diego, CA, the company will present results from a retrospective analysis characterizing the unmet need in enteric hyperoxaluria and an overview of the design of the ongoing Phase 3 URIROX-1 clinical trial evaluating the safety and efficacy of reloxaliase, its lead product candidate for the treatment of enteric hyperoxaluria.

Details on the presentations are as follows:

2018 ACR/ARHP Annual Meeting

Title: A Novel Recombinant Oral Urate Oxidase (UrOx) ALLN-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic UrOx Knockout (UrOxKO) Mice  
Session Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I  
Session Date and Time: Monday, October 22, 2018; 9:00 a.m. – 11:00 a.m. CT (10:00 a.m. – 12:00 p.m. ET)  
Location: Poster Hall, McCormick Place West  
Abstract ID: 1299  

The accepted abstract is now available online on the ACR/ARHP website at www.acrabstracts.org.

ASN Kidney Week 2018

Title: Unmet Need in Enteric Hyperoxaluria: Clinical Characteristics and Stone Burden in Patients from ALLN-177 Studies  
Session Title: Bone and Mineral Metabolism: Clinical - II  
Session Date and Time: Saturday, October 27, 2018; 10:00 a.m. – 12:00 p.m. PT (1:00 p.m.-3:00 p.m. ET)  
Location:
Abstract ID:
Exhibit Hall, San Diego Convention Center
SA-PO685
 


Title: Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria (UriRox-1)  
Session Title: Informational Posters  
Session Date and Time: Thursday, October 25, 2018; 10:00 a.m. – 12:00 p.m. PT (1:00 p.m.-3:00 p.m. ET)  
Location:
Abstract ID:
Exhibit Hall, San Diego Convention Center
INFO34
 

The accepted abstracts are now available online on the ASN Kidney Week website at: https://www.asn-online.org/education/kidneyweek/2018/program-search-abstract.aspx.

About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannahd@sternir.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

Allena.jpg

Source: Allena Pharmaceuticals, Inc.